Evidence map›Paper›PMID 25563650›Full record

ArticleStem cell research & therapy2015

Synergistic effect of angiotensin II on vascular endothelial growth factor-A-mediated differentiation of bone marrow-derived mesenchymal stem cells into endothelial cells.

Izuagie Attairu Ikhapoh, Christopher J Pelham, Devendra K Agrawal

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Angiotensin II and TGF-International journal of stem cells · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. PROTECTIVE EFFECT OFAfrican journal of traditional, complementary, and alternative medicines : AJTCAM · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Izuagie Attairu IkhapohDepartment of Medical Microbiology and Immunology, Creighton School of Medicine, 2500 California Plaza, Omaha, NE, 68178-0405, USA. IzuagieAttairu@creighton.edu.
Christopher J PelhamDepartment of Biomedical Sciences, Creighton School of Medicine, 2500 California Plaza, Omaha, NE, 68178, USA. ChristopherPelham@creighton.edu.
Devendra K AgrawalDepartment of Medical Microbiology and Immunology, Creighton School of Medicine, 2500 California Plaza, Omaha, NE, 68178-0405, USA. dkagr@creighton.edu.
Creighton University · US

Funding

MESENCHYMAL STEM CELLS IN THE PREVENTION OF THROMBOSIS AND NEOINTIMAL HYPERPLASIAR01HL112597 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2012 to 2016
$3.8M
GENE THERAPY WITH SOCS-3 IN INTIMAL HYPERPLASIA AND IN-STENT RESTENOSISR01HL104516 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2011 to 2014
$2.4M
SMOOTH MUSCLE CELL PROLIFERATION IN HUMAN CORONARY ARTERY BYPASS GRAFTSR01HL090580 · NHLBI · CREIGHTON UNIVERSITY · PI AGRAWAL, DEVENDRA K. · 2009 to 2012
$1.4M
NHLBI NIH HHS R01 HL090580NHLBI NIH HHS R01HL090580NHLBI NIH HHS R01 HL104516NHLBI NIH HHS R01HL104516NHLBI NIH HHS R01 HL112597NHLBI NIH HHS R01HL 112597
6 · The paper itself

Abstract

introductionIncreased levels of angiotensin II (Ang II) and activity of Ang II receptor type 1 (AT1R) elicit detrimental effects in cardiovascular disease. However, the role of Ang II receptor type 2 (AT2R) remains poorly defined. Mesenchymal stem cells (MSCs) replenish and repair endothelial cells in the cardiovascular system. Herein, we investigated a novel role of angiotensin signaling in enhancing vascular endothelial growth factor (VEGF)-A-mediated differentiation of MSCs into endothelial cells (ECs).

methodsBone marrow was aspirated from the femurs of Yucatan microswine. MSCs were extracted via ficoll density centrifugation technique and were strongly immunopositive for MSC markers, CD44, CD90, and CD105, but negative for hematopoietic markers, CD14 and CD45. Subsequently, naïve MSCs were differentiated for 10 days in varying concentrations and combinations of VEGF-A, Ang II, and AT1R or AT2R antagonists. Markers specific to ECs were determined by FACS analysis.

resultsAT1R and AT2R expression and cellular localization was demonstrated in MSCs stimulated with VEGF-A and Ang II via quantitative RT-PCR and immunofluorescence, respectively. Differentiation of naïve MSCs in media containing Ang II (2 ng/ml) plus low-dose VEGF-A (2 ng/ml) produced a significantly higher percentage of cells that were positive for expression of EC markers (for example, platelet endothelial cell adhesion molecule, vascular endothelial Cadherin and von Willebrand factor) compared to VEGF-A alone. Ang II alone failed to induce EC marker expression. MSCs differentiated with the combination of Ang II and VEGF-A were capable of forming capillary tubes using an in vitro angiogenesis assay. Induction of EC marker expression was greatly attenuated by co-treatment of Ang II/VEGF-A with the AT2R antagonist PD123319, but not the AT1R antagonist telmisartan.

conclusionsWe report the presence of functional AT2R receptor on porcine bone marrow-derived MSCs, where it positively regulates EC differentiation. These findings have significant implications toward therapeutic approaches based on activation of AT2R, which could be a means to stimulate regeneration of damaged endothelium and prevent vascular thrombosis.

Indexed as

Angiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersAnimalsAntigens, CDBenzimidazolesBenzoatesBone Marrow CellsCadherin 5CadherinsCell DifferentiationDrug SynergismEndothelial CellsFemurImidazolesMesenchymal Stem CellsAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersAntigens, CDBenzimidazolesBenzoatesCadherin 5CadherinsImidazolesPD 123319PyridinesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2RNA, Small InterferingTelmisartanVascular Endothelial Growth Factor Avon Willebrand Factor

Identifiers

PMID25563650
PMCPMC4417220
OpenAlexW2145291679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.